Drug search by name

Lapatinib Ditosylate and Cardiomyopathy

Result of checking the interaction of drug Lapatinib Ditosylate and disease Cardiomyopathy for safety when used together.

Check result:

Lapatinib Ditosylate <> Cardiomyopathy

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Cardiomyopathy was observed in clinical trials of certain EGFR inhibitors. Assess Left Ventricular Ejection Fraction (LVEF) by echocardiogram or multigated acquisition (MUGA) scan before initiation of these agents and then at 3 month intervals while on treatment. Caution is recommended when prescribing these agents to patients with conditions that could impair left ventricular function and it is recommended to withhold treatment with these agents if ejection fraction drops below the established lower limit of normal. For symptomatic congestive heart failure or persistent, asymptomatic LV dysfunction that does not resolve within 4 weeks, permanently discontinue these agents.

Lapatinib Ditosylate

Generic Name: lapatinib

Brand Name: Tykerb

Synonyms: Lapatinib

What is Lapatinib Ditosylate?